TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding TScan Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 81 | 1 | 73 | −7 |
| Shares | 35.7M | 18 | 34.6M | −1.12M (−3.1%) |
| Value | $51.8M | $26 | $62.9M | +$11.1M (+21.4%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (5)
Institutions that held TScan Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Voleon Capital Management LP | 47,879 | $87.1K | 0.00% |
| LPL Financial LLC | 21,500 | $39.1K | 0.00% |
| XTX Topco Ltd | 17,626 | $32.1K | 0.00% |
| Prudential Financial Inc | 11,500 | $20.9K | 0.00% |
| Rockefeller Capital Management L.P. | 200 | $364 | 0.00% |
Sold out (12)
Institutions that held TScan Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Troluce Capital Advisors LLC | 150,000 | $217.5K |
| Y-Intercept (Hong Kong) Ltd | 76,660 | $111.2K |
| HRT Financial LP | 55,369 | $80.0K |
| Jain Global LLC | 37,888 | $54.9K |
| Boothbay Fund Management, LLC | 24,363 | $35.3K |
| Squarepoint Ops LLC | 22,497 | $32.6K |
| AQR Capital Management LLC | 22,438 | $32.5K |
| Charles Schwab Investment Management Inc | 22,171 | $32.1K |
| Dynamic Technology Lab Private Ltd | 13,878 | $20.0K |
| DRW Securities, LLC | 10,132 | $14.7K |
| Wells Fargo & Company | 323 | $468 |
| Essential Partners LLC | 11 | $16 |
Not filed for Q3 2025 yet (1)
Institutions that held TScan Therapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Atlas Capital Advisors LLC | 18 | $26 |